

Amendments to the Claims

This listing of the claims as amended will replace all prior versions, and listings, of claims in the application.

1-55. (Canceled)

56. (Currently amended) A method of treating a subject having a disorder or condition characterized by an unwanted immune response comprising administering an effective amount of ~~an early activation molecule depletor~~ a depleting anti-CD69 antibody molecule, wherein the anti-CD69 antibody specifically binds SEQ ID NO:2 to the subject.

57-58. (Canceled)

59. (Currently amended) The method of claim ~~58~~56, wherein said depletor is a depleting anti-CD69 antibody molecule selected from the group consisting of: a humanized anti-CD69 antibody molecule, a human anti-CD69 antibody molecule, a chimeric anti-CD69 antibody molecule and a deimmunized anti-CD69 antibody molecule.

60. (Original) The method of claim 59, wherein said human anti-CD69 antibody molecule is a monoclonal antibody.

61-66. (Canceled)

67. (Original) The method of claim 56, wherein said disorder is an acute or chronic inflammatory disorder, or an immune disorder.

68. (Original) The method of claim 67, wherein said disorder is an autoimmune disorder.

69. (Original) The method of claim 56, wherein the disorder is selected from the group consisting of: rheumatoid arthritis, systemic lupus erythematosus, scleroderma, Sjögren

syndrome, autoimmune diabetes, thyroiditis, and other organo-specific immune diseases, including psoriasis.

70. (Withdrawn) The method of claim 56, wherein the disorder is a neurological disorder, a gastrointestinal disorder, a cardiovascular disorder or a respiratory disorder.

71. (Withdrawn) The method of claim 70, wherein the disorder is a neurological disorder and the neurological disorder is selected from the group consisting of: multiple sclerosis, myasthenia gravis, and other neurological immune-mediated diseases.

72. (Withdrawn) The method of claim 70, wherein the disorder is a gastrointestinal disorder and the gastrointestinal disorder is selected from the group consisting of Crohn's disease, colitis, celiac disease, and hepatitis.

73. (Withdrawn) The method of claim 70, wherein the disorder is a respiratory disorder and the respiratory disorder is selected from the group consisting of: emphysema, and respiratory airways infections.

74. (Withdrawn) The method of claim 70, wherein the disorder is a cardiovascular disorder and the cardiovascular disorder is selected from the group consisting of: atherosclerosis, cardiomyopathy, rheumatic fever, endocarditis, vasculitis, and other immune-mediated diseases.

75. (Withdrawn) The method of claim 56, wherein the disorder is an allergic process or a hypersensitivity reaction (type I, II, III, and IV), including asthma, rhinitis, and other immune-mediated hypersensitivity reactions.

76. (Withdrawn) The method of claim 56, wherein the disorder is transplant or graft rejection.

77. (Withdrawn) The method of claim 56, wherein said disorder or condition is: acute lung injury, acute respiratory distress syndrome, asthma, bronchitis, cystic fibrosis,

reperfusion injury, nephritis, pancreatitis, artery occlusion, stroke, transplantation, ultraviolet light induced injury, vasculitis, and sarcoidosis.

78-104. (Canceled)

105. (Currently amended) A method of treating a subject having a disorder or condition characterized by an unwanted immune response comprising administering an effective amount of ~~an antibody specific for an early activation molecule~~ a depleting anti-CD69 antibody molecule, wherein the anti-CD69 antibody specifically binds SEQ ID NO:2 to the subject, alone or conjugated to a second therapeutic agent.

106. (Original) The method of claim 105, wherein said second therapeutic agent is selected from the group consisting of: chemotherapeutic agents; radioisotopes; and cytotoxins.

107. (Original) The method of claim 105, wherein the antibody is a monoclonal antibody.

108. (Original) The method of claim 107, wherein the monoclonal antibody is a human antibody.